A new study demonstrated that trekkers and climbers taking a lower dose of acetazolamide (62.5 mg twice daily) were no more likely to develop acute mountain sickness (AMS) symptoms than those who took twice that amount, which is the standard prophylactic dose.
from Top Health News -- ScienceDaily https://ift.tt/2F7TS4N
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
It is looking at raising a debt of Rs 450 crore for the Eluru project and Rs 400 crore for the Bengaluru project, the official added from ...
-
With 73,642 new daily recoveries, the most so far, India's recovery rate has improved to 77.32%, while death rate has come down to 1.72%...
-
Modi said political stability through a massive mandate for his government alongside predictable policy provides a unique opportunity for In...
No comments:
Post a Comment